Distribution · MENA · Announced 22 Jun 2026
CEL-SCI → Saudi Amarox
Distribution deal between CEL-SCI (United States) and Saudi Amarox (Saudi Arabia), covering Leukocyte Interleukin, announced 22 Jun 2026. Value: Undisclosed.
Parties: CEL-SCI Corporation (United States) → SAUDI AMAROX (Saudi Arabia)
- Deal type
- Distribution
- Value
- Undisclosed
- Territory
- Saudi Arabia, Potential GCC
- Therapeutic area
- Oncology
- Asset
- Leukocyte Interleukin
- Announced
- 22 Jun 2026
Our analysis
Executive summary
CEL-SCI (NYSE American: CVM) has signed a distribution and revenue-sharing agreement with Riyadh-based Saudi Amarox for its investigational HNSCC immunotherapy Multikine.
Amarox will act as the local regulatory representative, lead all communication with the Saudi FDA, and pursue the SFDA's Breakthrough Medicine Designation; upon SFDA approval it gains exclusive distribution rights in the Kingdom, with an option to extend to the GCC.
The full analysis is free to read with a work email on this page.
Source: CEL-SCI Corporation